Fig. 1From: Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancerDistribution of EGFR, HER2, c-MYC, and MET genetic alterations according to (a) amplification data, (b) GCN gain results and (c) ASCO/CAP criterionBack to article page
